论文部分内容阅读
Charles River Laboratories International,Inc.(NYSE: CRL),a leadingglobal provider of research models and associated services andof preclinical drug development services,and WuXi PharmaTech(Cayman) Inc.(NYSE: WX),a leading drug research and developmentoutsourcing company with expertise in discovery chemistryand with operations in China and the United States,announced onApril 26th that they have signed a definitive agreement under whichCharles River and WuXi will combine in a cash and stock transactionvalued at approximately US$1.6 billion.The combined company,which will retain the name Charles River,
A leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading drug research and developmentoutsourcing company with Charles River Laboratories International, Inc. (NYSE: CRL) expertise in discovery chemistry and with operations in China and the United States, announced onApril 26th that they have signed a definitive agreement under whichCharles River and WuXi will combine in a cash and stock transactionvalued at approximately US $ 1.6 billion.The combined company, which will retain the name Charles River,